Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHIT-Immune: Dengue Challenge in Immune Participants
NCT06908018Phase 1Not yet recruiting
- Sponsor
- Mahidol University
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 1, open-label, single-arm trial of rDEN2Δ30-7169 in dengue fever, sponsored by Mahidol University. Primary endpoint: Safety of rDEN2Δ30-7169. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
rDEN2Δ30-7169
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT06908018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908018.